## Edgar Filing: AERIE PHARMACEUTICALS INC - Form 3/A

### **AERIE PHARMACEUTICALS INC** Form 3/A November 19, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

### OMB APPROVAL

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Mack David Henry	<ul><li>2. Date of Event Requiring Statement (Month/Day/Year)</li></ul>	3. Issuer Name and Ticker or Trading Symbol AERIE PHARMACEUTICALS INC [AERI]				
(Last) (First) (Middle)	10/25/2013	4. Relationshi Person(s) to I	ip of Reporting ssuer	5	5. If Amendment, Date Original Filed(Month/Day/Year)	
ONE EMBARCADERO CENTER, 37TH FLOOR		(Check all applicable)			10/25/2013	
(Street)		X_ Director Officer (give title below	Other		6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting	
SAN FRANCISCO, CA 94111					Person Form filed by More than One Reporting Person	
(City) (State) (Zip)	Table I - N	Non-Derivat	ive Securiti	ies Be	neficially Owned	
1.Title of Security (Instr. 4)	2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	1	
Reminder: Report on a separate line for owned directly or indirectly.	each class of securities benefic	ially S	EC 1473 (7-02	2)		
information cor	spond to the collection of tained in this form are not ond unless the form displ	t				

currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)		

## Edgar Filing: AERIE PHARMACEUTICALS INC - Form 3/A

(Instr. 5)

Option (right to buy)	(1)	09/12/2023	Common Stock	28,000 <u>(2)</u> \$ 3.15	D	Â
-----------------------	-----	------------	-----------------	---------------------------	---	---

# **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Iack David Henry DNE EMBARCADERO CENTER, 37TH FLOOR AN FRANCISCO, CA 94111	ÂX	Â	Â	Â	

# Signatures

M O Sz

David Mack 11/19/2013

<u>\*\*</u>Signature of Reporting Person Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on September 12, 2013. The option is exercisable as follows: on or after the 12th day of each successive month beginning October 12, 2013, the option may be exercised to purchase up to an additional 1/36th of the number of option shares.
- (2) Reflects a one-for-five reverse stock split of the Issuer's common stock effected October 8, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.